Practical Considerations for Treating Patients With Cancer in the COVID-19 Pandemic.


Journal

JCO oncology practice
ISSN: 2688-1535
Titre abrégé: JCO Oncol Pract
Pays: United States
ID NLM: 101758685

Informations de publication

Date de publication:
08 2020
Historique:
pubmed: 14 5 2020
medline: 29 8 2020
entrez: 14 5 2020
Statut: ppublish

Résumé

Cancer has become a prevalent disease, affecting millions of new patients globally each year. The COVID-19 pandemic is having far-reaching impacts around the world, causing substantial disruptions to health and health care systems that are likely to last for a prolonged period. Early data have suggested that having cancer is a significant risk factor for mortality from severe COVID-19. A diverse group of medical oncologists met to formulate detailed practical advice on systemic anticancer treatments during this crisis. In the context of broad principles, issues including risks of treatment, principles of prioritizing resources, treatment of elderly patients, and psychosocial impact are discussed. Detailed treatment advice and options are given at a tumor stream level. We must maintain care for patients with cancer as best we can and recognize that COVID-19 poses a significant competing risk for death that changes conventional treatment paradigms.

Identifiants

pubmed: 32401686
doi: 10.1200/OP.20.00229
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

467-482

Auteurs

Eva Segelov (E)

Department of Oncology, Monash University and Monash Health, Melbourne, Victoria, Australia.

Craig Underhill (C)

Border Medical Oncology, Albury-Wodonga Regional Cancer Centre, and University of NSW Rural Clinical School, Albury Campus, Albury, New South Wales, Australia.

Hans Prenen (H)

Department of Oncology, University Hospital Antwerp, Edegem, Belgium.

Christos Karapetis (C)

Department of Medical Oncology, Flinders Medical Centre, Flinders University, Adelaide, South Australia, Australia.

Christopher Jackson (C)

Department of Medicine, University of Otago, Dunedin, New Zealand.

Louise Nott (L)

Department of Medical Oncology, Royal Hobart Hospital, Hobart, Tasmania, Australia.

Tim Clay (T)

Department of Oncology, St John of God Subiaco Hospital and School of Medicine and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.

Nick Pavlakis (N)

Department of Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia.

Sabe Sabesan (S)

Department of Medical Oncology, Townsville Cancer Centre, Townsville Hospital and Health Services, Townsville, Queensland, Australia.

Ellen Heywood (E)

Cancer Services, Monash Health, Melbourne, Victoria, Australia.

Christopher Steer (C)

Border Medical Oncology, Albury-Wodonga Regional Cancer Centre, and University of NSW Rural Clinical School, Albury Campus, Albury, New South Wales, Australia.

Carrie Lethborg (C)

Inclusive Health Research, St Vincent's Health Australia, Melbourne, Victoria, Australia.

Hui K Gan (HK)

Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Victoria, Australia.
La Trobe University School of Cancer Medicine, Heidelberg, Victoria, Australia.
Department of Medicine, University of Melbourne, Heidelberg, Victoria, Australia.

Desmond Yip (D)

Department of Medical Oncology, The Canberra Hospital and ANU Medical School, Australian National University, Canberra, Australian Capital Territory, Australia.

Narayan Karanth (N)

Department of Medicine, Royal Darwin Hospital, Darwin, Northern Territory, Australia.

Deme Karikios (D)

Department of Medical Oncology, Nepean Hospital and Nepean Clinical School, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.

C Raina MacIntyre (CR)

Biosecurity Program, Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH